Researchers conducting the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial have found that the risk of life-threatening bleeding increases significantly through pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization without reducing the risk of major ischemic events in patients with non-ST-elevation acute coronary syndrome. The findings point to a "paradigm shift" away from pre-treatment ...
Read More
No comments:
Post a Comment